Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Placebo
100%
RNA Interference
100%
Mixed Hyperlipidemia
100%
Apolipoprotein C3
100%
Plozasiran
100%
Triglyceride Level
57%
95% Confidence Interval
57%
Percent Change
28%
Cholesterol Levels
28%
Triglyceride-rich Lipoproteins
28%
Fasting Triglycerides
28%
Small Interfering RNA (siRNA)
14%
Randomized Controlled Trial
14%
Randomized Placebo-controlled Trial
14%
Hepatocytes
14%
Metabolism
14%
Clinical Outcomes
14%
LDL Cholesterol
14%
Glycemic Control
14%
Subcutaneous Injection
14%
Atherosclerotic Cardiovascular Disease (ASCVD)
14%
Outcome Trials
14%
Non-high-density Lipoprotein Cholesterol (non-HDL-C)
14%
Low-density Lipoprotein Cholesterol Level
14%
Least Mean Square
14%
Non-high-density Lipoprotein
14%
Lipoprotein Lipase
14%
Remnant Cholesterol
14%
Change from Baseline
14%
Lipoproteins, HDL
14%
Biochemistry, Genetics and Molecular Biology
Triacylglycerol Level
100%
Hyperlipidemia
100%
Apolipoprotein C3
100%
RNAI
100%
High Density Lipoprotein Cholesterol Level
50%
Triglyceride-Rich Lipoprotein
50%
Metabolic Pathway
25%
Hepatocyte
25%
Glycemic Control
25%
Lipoprotein
25%
Randomized Controlled Trial
25%
Low Density Lipoprotein Cholesterol Level
25%
Diacylglycerol Lipase
25%
Cholesterol
25%
Small Interfering RNA
25%
Immunology and Microbiology
Triacylglycerol Level
100%
RNAI
100%
Apolipoprotein
100%
High Density Lipoprotein Cholesterol Level
50%
Lipoprotein
50%
Triglyceride-Rich Lipoprotein
50%
Low Density Lipoprotein Cholesterol Level
25%
Glycemic Control
25%
Cardiovascular System
25%
Ribonucleic Acid
25%
Pharmacology, Toxicology and Pharmaceutical Science
Hyperlipidemia
100%
Placebo
100%
Apolipoprotein C3
100%
Triacylglycerol
75%
High Density Lipoprotein Cholesterol
25%
Lipoprotein
25%
Small Interfering RNA
12%
Randomized Controlled Trial
12%
Subcutaneous Injection
12%
Low Density Lipoprotein Cholesterol
12%
Coronary Artery Atherosclerosis
12%
Lipoprotein Lipase
12%
Cholesterol
12%